Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  New England Journal of Medicine

• Publication date

  2015-01-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMoa1409002PMID 25629741PMCID PMC4358820
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea

  2014cited by this paper
• Iron and mechanisms of emotional behavior.

  2014cited by this paper
• Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.

  2014cited by this paper
• Baseline Characteristics and Symptom Burden in RESPONSE: A Randomized, Open-Label, Phase 3 Study of Ruxolitinib In Polycythemia Vera Patients Resistant to or Intolerant of Hydroxyurea

  2013cited by this paper
• Treatment Target in Polycythemia Vera

  2013cited by this paper
• Treatment target in polycythemia vera.

  2013cited by this paper
• A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

  2013cited by this paper
• Emerging drugs for polycythemia vera

  2013cited by this paper
• Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms

  2013cited by this paper
• Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study

  2013cited by this paper
• Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis

  2013cited by this paper
• Cardiovascular events and intensity of treatment in polycythemia vera.

  2013cited by this paper
• Treatment target in polycythemia vera.

  2013cited by this paper
• Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.

  2013cited by this paper
• Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha.

  2013cited by this paper
• Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera.

  2012cited by this paper
• Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort.

  2012cited by this paper
• Polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management

  2011cited by this paper
• The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera

  2011cited by this paper
• The renaissance of interferon therapy for the treatment of myeloid malignancies.

  2011cited by this paper
• Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980.

  2011cited by this paper
• Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms.

  2011cited by this paper
• Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

  2011cited by this paper
• Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3

  2011cited by this paper
• High prevalence of restless legs syndrome among patients with polycytemia vera treated with venesectio

  2010cited by this paper
• A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process

  2010cited by this paper
• Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?

  2009cited by this paper
• Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.

  2009cited by this paper
• Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms

  2008cited by this paper
• Factor XI deficiency

  2008cited by this paper
• Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.

  2008cited by this paper
• Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera.

  2007cited by this paper
• The burden of fatigue and quality of life in myeloproliferative disorders (MPDs)

  2007cited by this paper
• Variable bleeding manifestations characterize different types of surgery in patients with severe factor XI deficiency enabling parsimonious use of replacement therapy

  2006cited by this paper
• Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study.

  2005cited by this paper
• Polycythemia vera.

  2004cited by this paper
• Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia.

  2004cited by this paper
• Efficacy and safety of low-dose aspirin in polycythemia vera.

  2004cited by this paper
• Polycythemia vera: myths, mechanisms, and management.

  2002cited by this paper
• Polycythemia Vera and Essential Thrombocythemia

  2001cited by this paper
• Role of blood coagulation factor XI in downregulation of fibrinolysis

  2000cited by this paper
• Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis.

  1997cited by this paper
• Polycythemia vera.

  1990cited by this paper

• Targeting DDX5 using FL118 suppresses mTOR signaling and tumorigenicity in JAK2V617F-driven myeloproliferative neoplasms.

  2026cites this paper
• The Impact of Cytokines on Treatment and Prognosis in Myeloproliferative Neoplasms

  2026cites this paper
• Targeting JAK/STAT axis in solid tumors: resolving the therapeutic paradox through upstream suppression and downstream disruption

  2026cites this paper
• The Immunoregulatory and Hematopoietic Effects of Momelotinib in a Murine Bone Marrow Failure Model

  2026cites this paper
• A comparative study of hematologic response to ropeginterferon alfa-2b in hydroxyurea-resistant or intolerant polycythemia vera: a real-world data-based analysis

  2025influential citation
• Old Therapy, New Questions: Rethinking Phlebotomy in a Pharmacologic Landscape

  2025cites this paper
• Target practice: Opportunities for therapeutic intervention in CHIP and CCUS.

  2025cites this paper
• Aberrant activation of IL-6/JAK/STAT3/FOSL1 signaling induces renal abnormalities in a Xenopus model of Joubert syndrome-related disorders

  2025cites this paper
• Clinical and Molecular Insights of Arterial and Venous Thrombosis in Myeloproliferative Diseases—Case-Based Narrative Review

  2025cites this paper
• Long‐Term Safety Profile of Ruxolitinib in Chronic Myeloproliferative Neoplasms: A Comprehensive Real‐World Analysis

  2025cites this paper
• A loss-of-function human ADAR variant activates innate immune response and promotes bowel inflammation

  2025cites this paper
• Challenges in predicting hydroxyurea resistance and reducing thrombotic risk in polycythemia vera patients: unmasking the limits of its machine learning study

  2025influential citation
• Acute retinal necrosis during the systemic use of Janus kinase inhibitor

  2025cites this paper
• Different Colours of Polycythemia Vera: A Case Series

  2025cites this paper
• Current Advances in the Diagnosis and Treatment of Major Myeloproliferative Neoplasms

  2025cites this paper
• Interferon alpha-2b (IFNα2b) in precision oncology: Innovations in delivery and combinatorial immunotherapy

  2025cites this paper
• Polycythaemia vera

  2025cites this paper
• Asymmetric Hydrogenation of β-Azaaryl α,β-Unsaturated Nitriles: An Access to Ruxolitinib.

  2025cites this paper
• Impact of Angiotensin-Converting Enzyme Inhibitors on Disease Symptoms in Patients with Chronic Myeloproliferative Neoplasms

  2025cites this paper
• Hypertriglyceridemia‐Induced Acute Pancreatitis Associated with Ruxolitinib for Hemophagocytic Lymphohistiocytosis: A Case Report

  2025cites this paper
• CNT as a robust delivery vehicle for anti-breast cancer drugs: A combined DFT and in-silico study.

  2025cites this paper
• Subclonal emergence of polycythemia vera, chronic myelomonocytic leukemia, and chronic myeloid leukemia

  2025cites this paper
• European Guideline on Chronic Pruritus

  2025cites this paper
• Real-world analysis of polycythemia vera treatment reveals nonadherence to NCCN guidelines in a large proportion of patients

  2025cites this paper
• A case displaying the importance of JAK1 and JAK2 gene transcription in antifungal defense against coccidioidomycosis

  2025cites this paper
• Rusfertide rapidly decreases hematocrit in patients with suboptimally controlled polycythemia vera.

  2025cites this paper
• Long-term safety and effectiveness of ruxolitinib in Japanese patients with polycythemia vera: a post-marketing study

  2025influential citation
• Shifting treatment goals in myeloproliferative neoplasms: focusing on polycythemia vera.

  2025cites this paper
• Ruxolitinib-associated dual immune complications: HBV reactivation and warm autoimmune hemolytic anemia in a patient with polycythemia vera

  2025cites this paper
• Emerging Significance and Implications of a Durable Complete Molecular Remission in the Treatment of Polycythemia Vera

  2025influential citation
• Malignant JAK-signaling: at the interface of inflammation and malignant transformation

  2025cites this paper
• Clinical outcomes of high-risk patients with polycythemia vera after suboptimal response to first-line therapy who switched to ruxolitinib versus nonswitchers: results from the PV-Switch study

  2025cites this paper
• Histone Phosphorylation in DNA Damage Response

  2025cites this paper
• Research trends in essential thrombocythemia from 2001 to 2024: a bibliometric analysis

  2025cites this paper
• The role of the JAK2-mediated inflammatory pathway in ischemic stroke

  2025cites this paper
• Prevalence, incidence, and thromboembolic events in polycythemia vera: a study based on longitudinal German health claims data

  2025cites this paper
• Prediction of resistance to hydroxyurea therapy in patients with polycythemia vera: a machine learning study (PV-AIM) validated in a prospective interventional phase IV trial (HU-F-AIM)

  2025cites this paper
• Population Pharmacokinetics‐Pharmacodynamics and Exposure‐Response of Ropeginterferon Alfa‐2b in Chinese and Japanese Patients With Polycythemia Vera

  2025cites this paper
• Second malignancies among older patients with classical myeloproliferative neoplasms treated with ruxolitinib

  2025cites this paper
• Infectious complications associated with immune and targeted anti-cancer therapies: a retrospective study of the FDA Adverse Events Reporting System (FAERS).

  2025cites this paper
• Health‐related quality of life and symptom profile of patients with BCR::ABL1‐negative myeloproliferative neoplasms: Real‐world evidence from the GIMEMA‐PROPHECY observational study

  2025influential citation
• Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design

  2025cites this paper
• Predictors of Symptom Scores in Myeloproliferative Neoplasms: A Real‐World Retrospective Cohort Study

  2025cites this paper
• A phase 1b study on the safety of Wharton's jelly mesenchymal stromal cells in the treatment of acute graft-versus-host disease.

  2025cites this paper
• Efficacy and safety of OB756 (a novel selective JAK2 inhibitor) for essential thrombocythemia in patients intolerant of or resistant to hydroxyurea or intolerant of interferon: A phase 2, open‐label, multicenter study

  2025cites this paper
• Recent advances and future perspectives in small molecule JAK2 inhibitors.

  2025cites this paper
• A pharmacovigilance study of adverse events associated with polycythemia vera treatments using the FDA Adverse Event Reporting System (FAERS) database

  2025cites this paper
• Network‐Based Drug Repurposing and Genomic Analysis to Unveil Potential Therapeutics for Monkeypox Virus

  2024cites this paper
• Systemic Inflammatory Index in Polycythemia Vera and Its Prognostic Implications

  2024cites this paper
• The evolving landscape of polycythemia vera therapies

  2024cites this paper
• The JAK1/JAK2 inhibitor ruxolitinib inhibits mediator release from human basophils and mast cells

  2024cites this paper
• Ropeginterferon alfa-2b shows anti-polycythaemia vera activity without causing clinically significant anaemia

  2024cites this paper
• Refractory pure red cell aplasia associated with T-cell large granular lymphocyte leukemia treated by ruxolitinib

  2024cites this paper
• The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1.

  2024cites this paper
• Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature

  2024cites this paper
• FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN)

  2024cites this paper
• Mathematical modelling of stem and progenitor cell dynamics during ruxolitinib treatment of patients with myeloproliferative neoplasms

  2024cites this paper
• Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice

  2024cites this paper
• The clonal hematopoiesis mutation Jak2V617F aggravates endothelial injury and thrombosis in arteries with erosion-like intimas.

  2024cites this paper
• Equitable access to polycythemia vera treatments: addressing reimbursement disparities in Europe

  2024cites this paper
• Bibliometric analysis of worldwide research on Polycythemia Vera in the 21st century

  2024cites this paper
• Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera.

  2024cites this paper
• Treatment‐associated decline in JAK2V617F allele burden in polycythemia vera: What does it mean?

  2024influential citation
• Cancer-associated thrombosis in hematologic malignancies

  2024cites this paper
• Localized eosinophilic cellulitis treated with topical ruxolitinib: A case report

  2024cites this paper
• Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management

  2024influential citation
• Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia

  2024influential citation
• Ten years of experience with ruxolitinib since approval for polycythemia vera: A review of clinical efficacy and safety

  2024cites this paper
• Using real-world evidence in haematology.

  2024cites this paper
• A 74-year-old woman with purple toes

  2024cites this paper
• A Review of Real-World Experience With Ruxolitinib for Myelofibrosis.

  2024cites this paper
• Advances in the design and discovery of next-generation janus kinase-2 (JAK2) inhibitors for the treatment of myeloproliferative neoplasms

  2024cites this paper
• Pathogenesis and management of high molecular risk myeloproliferative neoplasms

  2024cites this paper
• What is the optimal strategy for secondary prevention after venous thromboembolism in polycythemia vera?

  2024cites this paper
• Clonal evolution: a landmark of MPN evolution

  2024cites this paper
• Iron deficiency and phlebotomy in patients with polycythemia vera

  2024cites this paper
• Differences in Clinical Outcomes Between Hydroxyurea-Resistant and -Intolerant Polycythemia Vera Patients

  2024cites this paper
• Risk of Severe Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies

  2024cites this paper
• Assessing pharmacokinetics and drug-drug interactions of the combination therapy of myelofibrosis with ruxolitinib and lenalidomide by a new eco-friendly HPLC method for their simultaneous determination in plasma

  2024cites this paper
• JAK inhibitor selectivity: new opportunities, better drugs?

  2024cites this paper
• Cardiovascular Toxicity of Antineoplastic Treatments in Hematological Diseases: Focus on Molecular Mechanisms to Improve Therapeutic Management

  2024cites this paper
• Deciphering JAK/STAT signaling pathway: A multifaceted approach to tumorigenesis, progression and therapeutic interventions.

  2024cites this paper
• A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone

  2024cites this paper
• Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management

  2024cites this paper
• Associations of the circulating levels of cytokines with the risk of myeloproliferative neoplasms: a bidirectional mendelian-randomization study

  2024cites this paper
• Polycythemia vera and essential thrombocythemia of intermediate-age: A real-life, multicenter analysis of first-line treatment approach.

  2024cites this paper
• Efficacy and safety of ruxolitinib vs best available therapy for polycythemia vera: An updated systematic review and meta‐analysis

  2024influential citation
• Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia

  2024cites this paper
• Polycythemia vera: past, present and future

  2024cites this paper
• Up-and-Coming Drugs for the Treatment of Vitiligo

  2024cites this paper
• Diagnosis and Treatment of Polycythemia Vera: A Review.

  2024cites this paper
• Impact of Phlebotomy on Quality of Life in Low-Risk Polycythemia Vera

  2024influential citation
• What are the future prospects for polycythemia vera pharmacotherapies for patients with hydroxyurea resistance?

  2024influential citation
• Applications of Biological Therapy for Latent Infections: Benefits and Risks

  2024cites this paper
• Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature

  2024cites this paper
• Ischemic stroke as an initial performance of polycythemia vera in young adults: A case report and literature review

  2024cites this paper
• Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera

  2024cites this paper
• The survivin/XIAP suppressant YM155 impairs clonal growth and induces apoptosis in JAK2V617F cells

  2024cites this paper
• Inflammation and Related Signaling Pathways in Acute Myeloid Leukemia

  2024cites this paper
• Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2V617F myeloproliferative neoplasms

  2023cites this paper